The table below shows Aquestive Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$14.81M
-$23.40M
-$10.38M
$8.82M
-$14.48M
-$14.10M
Capital expenditure
$52.00K
$135.00K
$29.00K
$2.00K
$104.00K
$103.00K
Investing cash flow
-$52.00K
-$135.00K
-$29.00K
-$2.00K
-$104.00K
-$103.00K
Dividends paid
-
-
-
AQST operating cash flow (10-K history)
Aquestive Therapeutics, Inc. reported operating cash flow of -$52.43M for fiscal year 2025. That is down 46.6% from -$35.76M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from $5.82M (FY 2017) to -$52.43M. Figures come from the company's audited annual reports as filed with the SEC.